The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Tips for Smoothing the Time-Consuming Prior Authorization Process

Tips for Smoothing the Time-Consuming Prior Authorization Process

January 17, 2020 • By Susan Bernstein

  • Tweet
  • Email
Print-Friendly Version / Save PDF

ATLANTA—Obtaining prior authorization to ensure services or prescription drugs are covered by a patient’s health plan consumes staff time, and delays or denials may cause patients to abandon treatment, according to speakers at the 2019 ACR/ARP Annual Meeting. In a session on Nov. 10, the experts shared tips to smooth the process.

You Might Also Like
  • Principles Would Streamline Prior Authorization Processes
  • Prior Authorization Struggle Continues
  • ACR Introduces Prior Authorization & Step Therapy Resolutions at AMA Meeting
Explore This Issue
January 2020
Also By This Author
  • 2014 ACR/ARHP Annual Meeting: Rheumatoid Arthritis Management Treatment Recommendations

Train Staff on Rheumatic Diseases

Prior authorization may be required due to quantity limits imposed by health plans on medications, step therapy requirements, to check if medications are excluded from a plan’s formulary or to ensure coverage for high-tier, expensive drugs. Staff training is the first important step, said Jessica Farrell, PharmD, associate professor of pharmacy practice at Albany College of Pharmacy and Health Sciences, New York.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

In a 2017 AMA survey of 1,000 practicing physicians, 64% reported they waited at least one business day for prior authorizations from health plans, 23% said they waited three to five business days for these approvals, 86% said time spent on prior authorization processes has increased over the past five years, and 78% reported that prior authorization delays or denials sometimes lead to prescribed treatments being abandoned by their patients.1

Rheumatology practices report significant delays in their patients’ access to treatments due to prior authorizations. One study in Arthritis Care & Research showed that 71% of 225 patients who were prescribed an infusible medication required a prior authorization and waited longer to receive their drug.2 More than 50% of rheumatology providers in the study reported their staffs spent up to 20 hours per week on prior authorizations.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

“This can … cause patients to be on higher doses of steroids while they wait, being in flares for longer periods of time, and their diseases being uncontrolled,” Dr. Farrell said. “This hurts patient outcomes.”

Prior Authorization Tips

Dr. Farrell suggested the following:

  • Invite a pharmacist or nurse educator to talk about diseases and FDA-approved therapies;
  • Train staff on common ICD-10 codes for rheumatic diseases to avoid clerical errors and recognize which codes often flag denials;
  • Create a comprehensive list of common medications currently approved for rheumatic diseases. Infusible medications may have different dosing regimens for each indication, so a plan may deny coverage due to the wrong dosing regimen; and
  • For new staff, develop standardized work flows that include steps for prior authorizations to be reviewed by someone experienced in the process.
Dr. Farrell

Dr. Farrell

“Identify specific staff to handle certain prior authorizations, such as for infusibles, so they learn the process,” Dr. Farrell said. “They’ll develop their own tips and tricks and become more efficient.”

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Some electronic health record (EHR) systems include patient profiles with such details as medical history and past medication failures, so benefit investigations or appeals following coverage denials are easier to perform than in the past, said Dr. Farrell. EHRs may include calendars that show when a patient’s drug prior authorization will expire and needs to be renewed.

If coverage is denied, request an expedited appeal. Review denial letters to pinpoint the payer’s rationale, then respond with a letter that includes the patient’s medical history, past medication failures and evidence, such as abstracts, to support the requested therapy or as justification for off-label use. “If you get to a peer-to-peer review step of an appeal, you can also ask for a rheumatologist to review it. Many plans have specialists on staff who understand our disease states,” said Dr. Farrell.

Pages: 1 2 3 | Single Page

Filed Under: Practice Management, Workforce Tagged With: 2019 ACR/ARP Annual Meeting, pharmacy benefit managers (PBMs), prior authorization, step therapyIssue: January 2020

You Might Also Like:
  • Principles Would Streamline Prior Authorization Processes
  • Prior Authorization Struggle Continues
  • ACR Introduces Prior Authorization & Step Therapy Resolutions at AMA Meeting
  • Reminder: How to Handle Part D Prior Authorization Requests

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Patient & Caregiver Resources

Find a rheumatology provider. Learn about your condition and how to live with it. English and Spanish language resources.

View Patient & Caregiver Resources »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)